Purpose: The aim of this study was to evaluate the diagnostic performance of a computer-aided detection (CAD) system used with automated breast ultrasonography (ABUS) for suspicious lesions detected on breast MRI, and CAD-false lesions.
INTRODUCTION
Automated breast ultrasonography (ABUS) has been developed in recent decades and proposed as a promising tool for overcoming the disadvantages of hand-held ultrasonography (HHUS) (1) . Although HHUS technology has progressed and is still the This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. standard breast US method, it is operator-dependent and nonreproducible, and cannot display breast lesions in the coronal plane (2, 3) .
ABUS was primarily developed as a screening tool. Unlike HHUS, it is less operator-dependent and can acquire full three-dimensional breast US volumes that are reproducible any time. To provide complete coverage of both breasts, ABUS consists of two to five acquisitions per breast, with each acquisition comprising over 300 transverse and reconstructed images in the coronal and sagittal planes. Consequently, the large ABUS volumes might induce oversight errors involving specific malignancies. Accurate computer-aided detection (CAD) software may facilitate the detection of cancers in ABUS data sets and enhance the efficiency of radiologist work flows (4) .
Research using CAD for ABUS is not exhaustive, with few studies using CAD with ABUS for suspicious lesions detected on breast MRI.
The purpose of this study was to evaluate the diagnostic performance of CAD with ABUS for suspicious lesions detected on breast MRI and to analyze the nature of CADdetected lesions and determine the factors triggering false readings.
MATERIALS AND METHODS

Patient Population
The Institutional Review Board approved the study. All patients provided informed consent for the study. Between January 1 and December 31, 2017, we prospectively enrolled 40 women (age range, 30-76 years; mean age, 50.4 ± 9.8 years) who underwent HHUS and ABUS for multiple suspicious lesions detected on preoperative MRI. The 40 patients carried a total of 122 suspicious lesions under categories 4, 5, and 6 based on the American College of Radiology Breast Imaging Reporting and Data System (ACR BI-RADS). Most lesions were ultimately diagnosed using ultrasound-guided needle biopsy or surgical results.
Of the 122 MRI-detected lesions, we excluded 51 daughter nodules located near the main breast cancer within the same quadrant, ultimately including 71 lesions: 49 identified as malignant, 15 as nonmalignant, and 7 lesions with no change or that disappeared on followup MRI. Among the 64 pathologically confirmed lesions, 58 were confirmed via ultrasound-guided biopsy, 4 via mammography-guided biopsy, 1 was confirmed via ultrasound-guided localization prior to surgery, and 1 was confirmed via MRI-guided biopsy. 
Breast MRI
All patients underwent MR imaging of the breast at our institution, performed with a 3T MR imaging system (Ingenia, Philips, Eindhoven, The Netherlands and Verio, Siemens Medical Solutions, Erlangen, Germany). Images of both breasts were obtained in the axial plane with the patient lying in the prone position. In this study, the following sequences were used: axial, turbo spin-echo T2-weighted imaging ( 
ABUS and CAD Systems
ABUS was performed using the automated breast volume scanner ACUSON S2000 ABUS system (Siemens Medical Solutions, Mountain View, CA, USA) by an experienced radiographer. The radiographer selected the most suitable setting based on the patient's breast size (A-D and DD cups). With the patient in the supine position, anterior-posterior views of the bilateral breasts were initially scanned followed by scanning of the lateral and medial views, which primarily include the outer and the inner breast, in the oblique position. After the image acquisition, the 3D volume data were immediately sent to the workstation and reviewed in multiple orientations (transverse, coronal, and sagittal planes) using multi-planar reconstruction. The scan thickness was displayed at 1-mm intervals without overlap.
In this study, we used QVCAD tm CAD software (QVCAD system from QView Medical, Inc., Los Altos, CA, USA) to process and display ABUS images on a computer monitor for review with certain areas highlighted or marked for attention. It highlights suspicious regions displayed on an intelligent minimum intensity projection image of the ABUS view.
Image Analysis
Two specialized breast radiologists with 9 and 11 years of experience, respectively, in academic breast imaging reviewed 40 patients' breast MRIs, and categorized each suspicious lesion by BI-RADS. The CAD-detected lesions that matched suspicious lesions on MRI, were identified and analyzed.
Statistical Analysis
We statistically analyzed the diagnostic accuracy of CAD, characteristics of CAD-detected lesions and the causes underlying false-positive and false-negative cases, and false readings in general. We calculated the diagnostic performance-sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV)-using SAS version 9.2 (SAS Institute, Cary, NC, USA). We then analyzed the characteristics of the CAD-detected lesions using the chi-square test or the Fisher's exact test and calculated the P values, assuming significance at p less than 0.05.
RESULTS
The final proportions of malignant and benign lesions in this study were 52.1% (49/94) and 47.9% (45/94), respectively. CAD revealed 62 lesions (62/94, 65.9%) including 35 IDC lesions, 1 mucinous carcinoma, and 1 invasive lobular carcinoma (Table 2 ). Among the malignant (Table 3) . CAD also revealed 90.3% (28/31) of the invasive ductal cancers measuring larger than 1 cm mass (excluding non-masses and lesions smaller than 1 cm). Among the 71 MRI-detected lesions, 55 were mass lesions on MRI, 15 were non-mass lesions, and 1 was missed. Masses larger than 1 cm in size were detected at a significantly higher rate (P < 0.05), even with invasive ductal cancers that showed masses (Table 4 , Fig. 1 ).
False-negative lesions included 8 IDC lesions, 2 mucinous carcinomas, and 2 DCIS lesions. The mean sizes of the true-positive versus false-negative mass lesions were 2.08 ± 0.85 cm versus 1.6 ± 1.28 cm (P < 0.05). The falsepositive lesions included a sclerosing adenosis and a case of usual ductal hyperplasia. Additionally, the false CAD marks for pseudo lesions involved 18 marginal or subareolar shadowings, 3 simple cysts, a hematoma, and a skin wart (Fig. 2 ). Table 4 also shows the correlation between CADpositive lesions based on MRI and ABUS findings.
DISCUSSION
HHUS showed promising results as a breast cancer screening tool in the past decade. However, it remains somewhat challenging and time-consuming for radiologists. ABUS may address these limitations by greatly reducing operator dependency and providing high-resolution 3D images (5) . Although ABUS has many advantages over HHUS, it is still associated with a few disadvantages.
In a number of prior studies, the mean diameters of ABUS-detected lesions were larger than those of the handheld-detected lesions, with varying cut-offs (2, 6, 7). Therefore, it is possible that ABUS reflects the CAD detection sensitivity, especially in size. In this study, the mean sizes of the true-positive versus false-negative mass lesions were 2.08 ± 0.85 cm vs. 1.6 ± 1.28 cm (P < 0.05).
In previous studies, Chang et al. (8) reported statistically significant differences in ABUS detection rates of factors including margin, orientation, and boundary, and van Zelst et al. (9) suggested that a higher BI-RADS category indicated a higher detection rate on ABUS. In our study, the lesion shape, orientation, and margin showed statistically significant differences in CAD detection rate (P < 0.01) on ABUS. ABUS provides volumetric images with many slices and large FOV, which can lead to fatigue and missed radiological findings involving the large FOV, leading to interpretation errors, and ultimately decreasing the accuracy of detection. Skilled and accurate interpretation of ABUS requires considerable radiological training and experience (10) . Therefore, a CAD system with ABUS may be more feasible for radiologists in practice. Previous studies have shown positive results supporting the diagnostic utility of CAD with ABUS (4, 11) . As shown in our study, the sensitivity, specificity, PPV, and NPV of CAD with automated breast ultrasound were 75.5%, 44.4%, 59.7%, and 62.5%, respectively. The sensitivity of this study was relatively low (75.5%), because we used the CAD with ABUS for suspicious lesions detected on breast MRI. Breast MRI has proven to be the most sensitive tool for detecting breast carcinoma (12) .
Therefore, we enrolled patients with multiple suspicious lesions on preoperative MRI, and included many small and subtle lesions in this study.
Our study analyzed the diagnostic performance of ABUS with CAD for lesions detected using MRI. MR-directed ultrasound, also referred to as second-look ultrasound and targeted ultrasound, has been shown to be useful in identifying lesions detected initially on MRI. In one previous study, the role of MRI was indispensable for preoperative assessment, although the combination of HHUS and ABUS showed the highest sensitivity. In addition, ABUS imaging was better than HHUS for preoperative evaluation (6) .
We analyzed MRI lesions that correlated with detection rates on CAD with ABUS, and the detection rate was slightly higher if a lesion on MRI was defined as a mass (31/55, 56.4%) rather than a non-mass (7/15, 46.7%) lesion. This result suggests the same trend, albeit weaker, as that of a previous study in which the HHUS detection rates were a b 
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58% for mass versus 29% for non-mass lesions (13, 14) , and the pathologically invasion by malignant lesions with space-occupying mass formation showed a higher detection rate. In our study, 81.4% (35/43) of the invasive ductal cancer was detected using CAD. CAD was used to detect 84.9% (28/33) of the invasive ductal mass cancers (exclude non-mass). We found a statistically significant correlation between CAD with ABUS detection rate and the size of the lesions characterized as masses on MRI. Masses measuring greater than 1 cm in size were more likely to be detected on CAD, although we did not find this association between size and the likelihood of non-mass lesions detected on MRI. The discrepancies between mass and non-mass lesions may be because mass lesions, defined as three-dimensional space-occupying lesions, are more readily defined with CAD on ABUS.
In this study, we found 23 false CAD marks. The false CAD marks for pseudo lesions were easily identified as benign rather than suspicious. The false readings on CAD were attributed to typical marginal or subareolar shadowing, simple cysts, a cystic hematoma, and a skin wart, not mimicking a true breast lesion.
Our study has a few limitations. First, the study comprised a relatively small sample that lacked representativeness. Second, in some cases biopsy was not confirmed, and this might have affected outcomes. Third, two radiologists independently reviewed the MRI and HHUS and MRI and ABUS; however, this study did not provide the radiologists' performance analysis such as inter-observer agreement. In this study, we focused on the diagnostic performance of CAD with ABUS and interpreted the lesions associated with errors in the CAD system. The last limitation of this study is that we were not always confident about the precise MRIultrasound correlations. However, we stipulated stringent criteria to determine the sonographic correlation, such as lesion position, size, and similarity in shape. As such, we can guarantee true MRI-ultrasound correlations.
In this study, we determined the diagnostic performance of CAD with ABUS for suspicious lesions detected on breast MRI, the characteristics of CAD-detected lesions, and the causes of false positives, false negatives, and false CAD marks. In conclusion, it was not difficult for operators familiar with CAD combined with ABUS to identify false CAD marks for pseudo lesions. We demonstrated that CAD with ABUS showed a reliable diagnostic performance for invasive ductal cancers involving masses larger than 1 cm.
